jeunejedi | Citation :
C'est beau de rêver 
|
c'est surtout beau de raconter n'importe quoi sans donner de source
http://ist.inserm.fr/BASIS/elgis/fqmr/rapp/DDD/509.pdf
Citation :
Depuis quinze ans, divers travaux ont cherché à mesurer les apports alimentaires
et/ou le statut biologique en vitamines et minéraux (marqueurs biochimiques) dans
la population française. Ces études ont permis de tirer un certain nombre de
conclusions au niveau de la population générale tout venant .
Il n'existe pas de signes évocateurs, dans la population générale en France, de
carences minérales et/ou vitaminiques majeures redevables de mesures de santé
publique autres que des recommandations en termes de conseils nutritionnels. Les
seules exceptions concernent:
·la carence en fer au cours de la grossesse, dont la fréquence et l'intensité
aboutissant à des anémies patentes est redevable d'une supplémentation adaptée et
suivie médicalement (Hercherg et coll., 1985; De Benaze et coll., 1989);
·les sujets âgés en institution, dont un certain nombre de travaux mettent en
évidence l'existence de déficiences minérales et vitaminiques multiples (vitamines
D, C...) (Monget et coll., 1996a; Galan et coll., 1997b);
·il n'existe pas d'études sur les populations marginales ou en situation de grande
précarité pour lesquelles le risque de non-couverture des besoins nutritionnels est
le plus élevé.
|
Citation :
Ce dont tu parles c'est le problème avec la vitamine E de synthèse.
La recherche est malheureusement bloquée du fait notamment que quasiment personne, et surtout pas les pouvoirs publics, ne se soucie des problèmes de santé que peut poser la complémentation par la vitamine E de synthèse. (source -> http://gestionsante.free.fr/vitamine_e.htm )
Un bon complément vitaminé sera forcément composé de vitamine E naturelle. Et cette dernière est très bénéfique, je te conseille de lire la page en entier sur la vitamine E.
|
Je parlais de la E, mais il y aussi la D, la A...
Aucune étude sérieuse et publié dans la littérature n'a jamais montré un seul benefice apporté par la prise de vitamine E. Il y a eu de gros espoirts suite a des pré-etudes prometeuses mais qui se sont toutes révélés decevantes.
Idem pour la vitamine A qui devait proteger du cancer du poumon, et qui s'est révélé toxique aux doses soit disant protectrices.
Tiens un article de 2005 montrant les effets paradoxal de la vitamine E en augmentant le risque de recidive cancéreuse. Niveau de preuve I.
Citation :
A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.
Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, Mercier JP, Tetu B, Harel F, Masse B, Vigneault E, Vass S, del Vecchio P, Roy J.
Centre de Recherche en Cancerologie de L'Universite Laval, Quebec City, Quebec, Canada.
BACKGROUND: Although low dietary intakes of antioxidant vitamins and minerals have been associated with higher risks of cancer, results of trials testing antioxidant supplementation for cancer chemoprevention have been equivocal. We assessed whether supplementation with antioxidant vitamins could reduce the incidence of second primary cancers among patients with head and neck cancer. METHODS: We conducted a multicenter, double-blind, placebo-controlled, randomized chemoprevention trial among 540 patients with stage I or II head and neck cancer treated by radiation therapy between October 1, 1994, and June 6, 2000. Supplementation with alpha-tocopherol (400 IU/day) and beta-carotene (30 mg/day) or placebo began on the first day of radiation therapy and continued for 3 years after the end of radiation therapy. In the course of the trial, beta-carotene supplementation was discontinued after 156 patients had enrolled because of ethical concerns. The remaining patients received alpha-tocopherol or placebo only. Survival was evaluated by Kaplan-Meier analysis. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: After a median follow-up of 52 months, second primary cancers and recurrences of the first tumor were diagnosed in 113 and 119 participants, respectively. The effect of supplementation on the incidence of second primary cancers varied over time. Compared with patients receiving placebo, patients receiving alpha-tocopherol supplements had a higher rate of second primary cancers during the supplementation period (HR = 2.88, 95% CI = 1.56 to 5.31) but a lower rate after supplementation was discontinued (HR = 0.41, 95% CI = 0.16 to 1.03). Similarly, the rate of having a recurrence or second primary cancer was higher during (HR = 1.86, 95% CI = 1.27 to 2.72) but lower after (HR = 0.71, 95% CI = 0.33 to 1.53) supplementation with alpha-tocopherol. The proportion of participants free of second primary cancer overall after 8 years of follow-up was similar in both arms. CONCLUSIONS: alpha-Tocopherol supplementation produced unexpected adverse effects on the occurrence of second primary cancers and on cancer-free survival.
|
Une autre pour rire, sur le risque de cancer et cardiovasculaire:
Citation :
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR; HOPE and HOPE-TOO Trial Investigators.
Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario.
CONTEXT: Experimental and epidemiological data suggest that vitamin E supplementation may prevent cancer and cardiovascular events. Clinical trials have generally failed to confirm benefits, possibly due to their relatively short duration. OBJECTIVE: To evaluate whether long-term supplementation with vitamin E decreases the risk of cancer, cancer death, and major cardiovascular events. DESIGN, SETTING, AND PATIENTS: A randomized, double-blind, placebo-controlled international trial (the initial Heart Outcomes Prevention Evaluation [HOPE] trial conducted between December 21, 1993, and April 15, 1999) of patients at least 55 years old with vascular disease or diabetes mellitus was extended (HOPE-The Ongoing Outcomes [HOPE-TOO]) between April 16, 1999, and May 26, 2003. Of the initial 267 HOPE centers that had enrolled 9541 patients, 174 centers participated in the HOPE-TOO trial. Of 7030 patients enrolled at these centers, 916 were deceased at the beginning of the extension, 1382 refused participation, 3994 continued to take the study intervention, and 738 agreed to passive follow-up. Median duration of follow-up was 7.0 years. INTERVENTION: Daily dose of natural source vitamin E (400 IU) or matching placebo. MAIN OUTCOME MEASURES: Primary outcomes included cancer incidence, cancer deaths, and major cardiovascular events (myocardial infarction, stroke, and cardiovascular death). Secondary outcomes included heart failure, unstable angina, and revascularizations. RESULTS: Among all HOPE patients, there were no significant differences in the primary analysis: for cancer incidence, there were 552 patients (11.6%) in the vitamin E group vs 586 (12.3%) in the placebo group (relative risk [RR], 0.94; 95% confidence interval [CI], 0.84-1.06; P = .30); for cancer deaths, 156 (3.3%) vs 178 (3.7%), respectively (RR, 0.88; 95% CI, 0.71-1.09; P = .24); and for major cardiovascular events, 1022 (21.5%) vs 985 (20.6%), respectively (RR, 1.04; 95% CI, 0.96-1.14; P = .34). Patients in the vitamin E group had a higher risk of heart failure (RR, 1.13; 95% CI, 1.01-1.26; P = .03) and hospitalization for heart failure (RR, 1.21; 95% CI, 1.00-1.47; P = .045). Similarly, among patients enrolled at the centers participating in the HOPE-TOO trial, there were no differences in cancer incidence, cancer deaths, and major cardiovascular events, but higher rates of heart failure and hospitalizations for heart failure. CONCLUSION: In patients with vascular disease or diabetes mellitus, long-term vitamin E supplementation does not prevent cancer or major cardiovascular events and may increase the risk for heart failure.
|
Etc, etc etc...
Bref il faut vraiment arrete de raconter n'importe quoi et se documenter sur des sources sérieuses internationales (en suivant medline), et arreter de croire a des théories vieilles de 15 ans (les vitamines protegent du cancer), qui ont été maintes fois démontés par la suite, et qui sont toujours entretenus par les petits marchands de poudre de perlinpinpin 
Message édité par jeunejedi le 04-05-2005 à 14:34:23
|
![[:spamafote]](https://forum-images.hardware.fr/images/perso/spamafote.gif "[:spamafote]")
justement par exemple du même labo que sargenor, sargeform (je cite celui ci parce que tu as parlé de sargenor):
![[:figti]](https://forum-images.hardware.fr/images/perso/figti.gif "[:figti]")
), c'est bizarre que ce type de produit soit à ce point discrédité (ta réaction est justement l'archétype des a priori à ce sujet)...
![[:zaib3k]](https://forum-images.hardware.fr/images/perso/zaib3k.gif "[:zaib3k]")
![[:airforceone]](https://forum-images.hardware.fr/images/perso/airforceone.gif "[:airforceone]")
. Une des raisons est qu'en forte quantite une partie des molecules vont etre pro-oxidantes au lieu d'etre anti-oxidantes (anti-oxidant => piege les radicaux libres or les radicaux libres 
peuvent attaquer l'ADN par exemple donc peuvent entrainer des cancers). 
Mais si on a une baisse d'energie, rien n'empeche d'en prendre un peu en supplement (faut pas que ca devienne une habitude...).
).
Et finis tes epinards avant de sortir de table!![[:zjk]](https://forum-images.hardware.fr/images/perso/zjk.gif "[:zjk]")